Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)
Authors
Middleton, M. R.Hamid, O.
Shoushtari, A. N.
Meier, F. E.
Bauer, T. M.
Salama, A. K. S.
Kirkwood, J. M.
Ascierto, P. A.
Lorigan, Paul C
Mauch, C.
Orloff, M. M.
Evans, T. R. J.
Abdullah, S. E.
Yuan, Y.
Mitchell, J.
Hassel, J. C.
Affiliation
University of Oxford, OxfordIssue Date
2022
Metadata
Show full item recordCitation
Middleton MR, Hamid O, Shoushtari AN, Meier FE, Bauer TM, Salama AKS, et al. Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680300099.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.104Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.104Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.104